BioSpace News Archive

Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream” or the “Company”) is providing webcast access to their virtual R&D Day, being held on Tuesday, February 14, 2023.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter and full year ended December 31, 2022.

DiaSorin (FTSE MIB: DIA) and Cytek Biosciences, Inc.(Nasdaq: CTKB) today announced that Luminex Corporation, a wholly owned subsidiary of DiaSorin, has signed an agreement with Cytek to sell substantially all of its assets related to the Flow Cytometry & Imaging (FCI) business unit.

TC BioPharm (Holdings) PLC (“TC BioPharm” or the “Company”) (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced that it now plans to host its shareholder update call on Tuesday, February 21, 2023, at 12:00 p.m. ET.

Aethlon Medical, Inc. reported financial results for its third quarter ended December 31, 2022 and provided an update on recent developments.

Acadia Pharmaceuticals Inc. announced that on February 10, 2023, the Compensation Committee of Acadia’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 310,065 shares of common stock and 97,251 restricted stock units to 19 new employees under Acadia’s 2023 Inducement Plan.

Johnson & Johnson announced the appointment of John Reed, M.D., Ph.D., to the Company’s Executive Committee as Executive Vice President of Pharmaceuticals, R&D.

Procaps Group, a leading integrated LatAm healthcare and pharmaceutical conglomerate, issued a letter to shareholders from Ruben Minski, Chairman of the Board and CEO of Procaps, including preliminary select financial results for the fiscal year ended December 31, 2022 and guidance on its near term growth prospects.

Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions, will report its financial results for the quarterly period and full year ended December 31, 2022 after the close of the market on Monday, February 27, 2023.

BioXcel Therapeutics, Inc. today announced full data from its Phase 2a trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer.